Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.33 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
| ▸ | KCND3 | Q9UK17 | 1/20 | 0.33 |
| ▸ | CYP51A1 | Q16850 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1842366 | 1.00 | KDM4E (0.34) | KDM4EALDH1A1L3MBTL1KCNA5KCNJ5 | |
| SCHEMBL1842364 | 1.00 | KDM4E (0.34) | KDM4EALDH1A1L3MBTL1KCNA5KCNJ5 | |
| SCHEMBL4250379 | 0.93 | KDM4E (0.33) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4250383 | 0.93 | KDM4E (0.33) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL13949330 | 0.91 | KDM4E (0.35) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL4247031 | 0.91 | KDM4E (0.35) | KDM4EALDH1A1L3MBTL1 | |
| SCHEMBL12662665 | 0.90 | KDM4E (0.35) | KDM4EALDH1A1L3MBTL1KCNA5KCNJ5 | |
| SCHEMBL4244124 | 0.82 | KCNA5 (0.34) | KCNA5KCNJ5KCNJ3SCN5AKCND3 | |
| SCHEMBL5178096 | 0.82 | KCNA5 (0.34) | KCNA5KCNJ5KCNJ3SCN5AKCND3 | |
| SCHEMBL4245779 | 0.81 | KDM4E (0.35) | KDM4EALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1848709-B1 | NOVEL SALT FORM OF A DOPAMINE AGONIST | PFIZER LTD (GB) | 2011-05-18 | — | — | EP | disclosed |
| US-7498329-B2 | Salt form of dopamine agonist | PFIZER INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20060183740-A1 | Novel salt form of a dopamine agonist | PFIZER INC | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183740-A1 | Novel salt form of a dopamine agonist | SLC6A3, CHRNA5, TACR2 | KDM4E 2433/4885ALDH1A1 2367/4885L3MBTL1 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.